SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Solbu Dag)
 

Sökning: WFRF:(Solbu Dag) > (2020) > Everolimus Initiati...

  • Gustafsson, FinnUniversity of Copenhagen,Copenhagen University Hospital,Rigshosp, Denmark; Univ Copenhagen, Denmark (författare)

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • LIPPINCOTT WILLIAMS & WILKINS,2020
  • 11 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:4f96f99b-ca04-4eb7-9dac-42f0df5c560d
  • https://lup.lub.lu.se/record/4f96f99b-ca04-4eb7-9dac-42f0df5c560dURI
  • https://doi.org/10.1097/TP.0000000000002702DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-165665URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • BACKGROUND: A calcineurin inhibitor (CNI)-free immunosuppressive regimen has been demonstrated to improve renal function early after heart transplantation, but long-term outcome of such a strategy has not been well described. METHODS: In the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with reduced-exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 posttransplant or (2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients were followed up at 5-7 years posttransplant. RESULTS: Mean measured glomerular filtration rate was 74.7 mL/min and 62.4 mL/min with everolimus and CNI, respectively. The mean difference was in favor of everolimus by 11.8 mL/min in the intent-to-treat population (P = 0.004) and 17.2 mL/min in the per protocol population (n = 75; P < 0.001). From transplantation to last follow-up, the incidence of biopsy-proven acute rejection (BPAR) was 77% (37/48) and 66% (31/47) (P = 0.23) with treated BPAR in 50% and 23% (P < 0.01) in the everolimus and CNI groups, respectively; no episode led to hemodynamic compromise. Coronary allograft vasculopathy (CAV) assessed by coronary intravascular ultrasound was present in 53% (19/36) and 74% (26/35) of everolimus- and CNI-treated patients, respectively (P = 0.037). Graft dimensions and function were similar between the groups. Late adverse events were comparable. CONCLUSIONS: These results suggest that de novo heart transplant patients randomized to everolimus and low-dose CNI followed by CNI-free therapy maintain significantly better long-term renal function as well as significantly reduced CAV than patients randomized to standard CNI treatment. Increased BPAR in the everolimus group during year 1 did not impair long-term graft function.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Andreassen, Arne K.Oslo university hospital,Oslo Univ Hosp, Norway,Sahlgrens Univ Hosp, Sweden,Sahlgrenska University Hospital (författare)
  • Andersson, BertSahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden (författare)
  • Eiskjær, HansAarhus University Hospital,Aarhus Univ Hosp, Denmark (författare)
  • Rådegran, GöranLund University,Lunds universitet,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Skåne University Hospital,Lund Univ, Sweden; Lund Univ, Sweden(Swepub:lu)med-grd (författare)
  • Gude, EinarOslo university hospital,Oslo Univ Hosp, Norway (författare)
  • Jansson, Kjell,1956-Linköpings universitet,Linköping University,Östergötland County Council,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Fysiologiska kliniken US(Swepub:liu)kjeja02 (författare)
  • Solbu, DagNovartis Norge AS, Norway (författare)
  • Karason, KristjanSahlgrenska University Hospital (författare)
  • Arora, SatishOslo university hospital,Oslo Univ Hosp, Norway (författare)
  • Dellgren, GöranSahlgrenska University Hospital,Sahlgrens Univ Hosp, Sweden (författare)
  • Gullestad, LarsUniversity of Oslo,Oslo university hospital,Oslo Univ Hosp, Norway; Univ Oslo, Norway; Univ Oslo, Norway (författare)
  • University of CopenhagenCopenhagen University Hospital (creator_code:org_t)
  • SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators

Sammanhörande titlar

  • Ingår i:Transplantation: LIPPINCOTT WILLIAMS & WILKINS104:1, s. 154-1641534-60800041-1337

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy